A Phase 1 interventional study of SHR7280 and Placebo oral tablet in Healthy Subjects, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-28.
Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR7280 tablets in healthy subjects.
GNRH antagonists can be used to treat sex hormone-dependent diseases, and SHR7280 is an oral GNRH antagonist. The purpose of this study is to observe the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple oral doses of SHR7280 in healthy subjects.
Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
PART 1:
PART 2:
Exclusion Criteria:
PART 1
PART 2:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
oral administration for 14 days,Phase I(PART 1)
Drug: SHR7280 · Drug: Placebo oral tablet
oral administration for 14 days,Phase I(PART 1)
Drug: SHR7280 · Drug: Placebo oral tablet
oral administration for 14 days,Phase I(PART 1)
Drug: SHR7280 · Drug: Placebo oral tablet
oral administration for 14 days,Phase I(PART 1)
Drug: SHR7280 · Drug: Placebo oral tablet
oral administration for 14 days,Phase I(PART 1)
Drug: SHR7280 · Drug: Placebo oral tablet
oral administration for 21 days,Phase I(PART 2)
Drug: SHR7280 · Drug: Placebo oral tablet
oral administration for 21 days,Phase I(PART 2)
Drug: SHR7280 · Drug: Placebo oral tablet
oral administration for 21 days,Phase I(PART 2)
Drug: SHR7280 · Drug: Placebo oral tablet
oral administration for 21 days,Phase I(PART 2)
Drug: SHR7280 · Drug: Placebo oral tablet
oral administration for 14 days,Phase I(PART 1)
Drug: SHR7280 · Drug: Placebo oral tablet
oral administration for 14 days,Phase I(PART 1)
Drug: SHR7280 · Drug: Placebo oral tablet
treatment
blank control
Number of Participants with Adverse events
Part 1 and Part 2
Time frame: Pre-dose to 28±2 days after dose administration
Area under the plasma concentration versus time curve (AUCτ) after the first dose of SHR7280;
Part 1 and Part 2
Time frame: At pre-defined intervals from initial dose through final study visit( 28±2 days after dose administration)
Maximum observed serum concentration (Cmax) after the first dose of SHR7280;
Part 1 and Part 2
Time frame: At pre-defined intervals from initial dose through final study visit (28±2 days after dose administration)
Time to maximum observed serum concentration (Tmax) after the first dose of SHR7280;
Part 1 and Part 2
Time frame: At pre-defined intervals from initial dose through final study visit (28±2 days after dose administration)
Time to elimination half-life (T1/2) ;
Part 1 and Part 2
Time frame: At pre-defined intervals from initial dose through final study visit (28±2 days after dose administration)
Apparent total clearance(CL/F) of the drug from plasma after last morning dose of SHR7280;
Part 1 and Part 2
Time frame: At pre-defined intervals from initial dose through final study visit (28±2 days after dose administration)
Apparent volume of distribution(Vz/F) after last morning dose of SHR7280;
Part 1 and Part 2
Time frame: At pre-defined intervals from initial dose through final study visit (28±2 days after dose administration)
Maximum observed serum concentration (Cmax) after last morning dose of SHR7280;
Part 1 and Part 2
Time frame: At pre-defined intervals from initial dose through final study visit (28±2 days after dose administration)
Time to maximum observed serum concentration (Tmax) after last morning dose of SHR7280;
Part 1 and Part 2
Time frame: At pre-defined intervals from initial dose through final study visit (28±2 days after dose administration)
Trough observed serum concentration (Ctrough) after last morning dose of SHR7280;
Part 1 and Part 2
Time frame: At pre-defined intervals from initial dose through final study visit (28±2 days after dose administration)
Accumulation Factor(Racc)after last morning dose of SHR7280;
Part 1 and Part 2
Time frame: At pre-defined intervals from initial dose through final study visit (28±2 days after dose administration)
Area under the plasma concentration versus time curve (AUCτ) after last morning dose of SHR7280;
Part 1 and Part 2
Time frame: At pre-defined intervals from initial dose through final study visit (28±2 days after dose administration)
Endocrine Parameters: Testosterone
Part 1
Time frame: At pre-defined intervals from initial dose through final study visit (28±2 days after dose administration)
Endocrine Parameters: Estuarial
Part 2
Time frame: At pre-defined intervals from initial dose through final study visit (28±2 days after dose administration)
Endocrine Parameters:Progesterone
Part 2
Time frame: At pre-defined intervals from initial dose through final study visit (28±2 days after dose administration)
Endocrine Parameters: Luteinizing hormone
Part 2
Time frame: At pre-defined intervals from initial dose through final study visit (28±2 days after dose administration)
Endocrine Parameters: Follicle stimulating hormone
Part 2
Time frame: At pre-defined intervals from initial dose through final study visit (28±2 days after dose administration)
Plan to share: No — Hengrui shall own the exclusive rights to all results, data, findings, radiological \& diagnostic images, discoveries, inventions \& specifications, whether patentable or not, that are originated, conceived, derived, produced, discovered, invented or otherwise made by Center, PI and/or Study Team Physicians and/or Members in connection with the performance of the Study (i.e. Results).
No publications or documents are linked to this record.
Ran from Sep 2020 to primary completion in Sep 2021, 12 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GnRH Antagonist SHR7280
Jiangsu HengRui Medicine Co., Ltd. →